Risk stratification schemes for MGUS and SMM
| Risk stratification scheme . | No. of risk factors . | No. of patients (%) . | 20-year progression, % . | RR . |
|---|---|---|---|---|
| Mayo Clinic for MGUS patients55 Risk factors: M-protein > 1.5 g/dL, non-IgG MGUS, FLC ratio < 0.26 or > 1.65 | 0 | 449 (38) | 5 | 1 |
| 1 | 420 (37) | 21 | 5.4 | |
| 2 | 226 (20) | 37 | 10.1 | |
| 3 | 53 (5) | 58 | 20.8 | |
| Total | 1148 (100) | 20 | N/A |
| Risk stratification scheme . | No. of risk factors . | No. of patients (%) . | 20-year progression, % . | RR . |
|---|---|---|---|---|
| Mayo Clinic for MGUS patients55 Risk factors: M-protein > 1.5 g/dL, non-IgG MGUS, FLC ratio < 0.26 or > 1.65 | 0 | 449 (38) | 5 | 1 |
| 1 | 420 (37) | 21 | 5.4 | |
| 2 | 226 (20) | 37 | 10.1 | |
| 3 | 53 (5) | 58 | 20.8 | |
| Total | 1148 (100) | 20 | N/A |
| . | . | . | 5-year progression, % | . |
|---|---|---|---|---|
| Spanish study group for MGUS patients21 Risk factors: ≥ 95% aPC, DNA aneuploidy | 0 | 127 (46) | 2 | 1 |
| 1 | 133 (48) | 10 | 5 | |
| 2 | 16 (6) | 46 | 23 | |
| Total | 276* (100) | 8.5 | N/A | |
| Mayo Clinic for SMM patients20 Risk factors†: marrow plasma cells ≥ 10%, M-protein ≥ 3 g/dL, FLC ratio < 0.125 or > 8 | 1 | 76 (28) | 25 | 1 |
| 2 | 115 (42) | 51 | 2.0 | |
| 3 | 82 (30) | 76 | 3.0 | |
| Total | 273 (100) | 51 | N/A | |
| Spanish study group for SMM patients21 Risk factors: ≥ 95% aPC, immunoparesis | 0 | 28 (31) | 4 | 1 |
| 1 | 22 (25) | 46 | 11.5 | |
| 2 | 39 (44) | 72 | 18 | |
| Total | 89‡ (100) | 46 | N/A |
| . | . | . | 5-year progression, % | . |
|---|---|---|---|---|
| Spanish study group for MGUS patients21 Risk factors: ≥ 95% aPC, DNA aneuploidy | 0 | 127 (46) | 2 | 1 |
| 1 | 133 (48) | 10 | 5 | |
| 2 | 16 (6) | 46 | 23 | |
| Total | 276* (100) | 8.5 | N/A | |
| Mayo Clinic for SMM patients20 Risk factors†: marrow plasma cells ≥ 10%, M-protein ≥ 3 g/dL, FLC ratio < 0.125 or > 8 | 1 | 76 (28) | 25 | 1 |
| 2 | 115 (42) | 51 | 2.0 | |
| 3 | 82 (30) | 76 | 3.0 | |
| Total | 273 (100) | 51 | N/A | |
| Spanish study group for SMM patients21 Risk factors: ≥ 95% aPC, immunoparesis | 0 | 28 (31) | 4 | 1 |
| 1 | 22 (25) | 46 | 11.5 | |
| 2 | 39 (44) | 72 | 18 | |
| Total | 89‡ (100) | 46 | N/A |
MGUS indicates monoclonal gammopathy of undetermined significance; SMM, smoldering multiple myeloma; RR, relative risk; FLC, free light chain; N/A, not applicable; and aPC, aberrant plasma cell.
A total of 407 patients with MGUS were studied; 276 patients had available aneuploidy data.
Patients must have at least one of the first 2 risk factors to meet criteria for SMM.
A total of 93 patients with SMM were initially studied; 89 had available immunoparesis data.